Integrated Flow Injection-Solid Phase Spectrophotometric Determination of Minoxidil

Minoxidil was applied to a single miniaturized hair follicle over four months, resulting in less miniaturization but not yet terminal growth. The user used a 5% minoxidil solution, specifically the Regaine brand, and observed changes using a handheld WiFi microscope.

A 44-year-old man experienced significant hair regrowth after switching from topical to 1.25mg oral minoxidil and 0.5mg daily finasteride, with no side effects. He noticed hair thickening after two months and credits the oral form's effectiveness.

VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.

The user resumed finasteride and added 5mg oral minoxidil and biotin, noticing quick progress in hair regrowth. Other users discuss dosages and express surprise at the results.

A new extended-release oral minoxidil formulation claims to improve hair growth by maintaining steady blood levels, reducing side effects like hypotension, and potentially benefiting female hair loss. However, it is not considered groundbreaking as it builds on existing minoxidil treatments, and its effectiveness compared to current doses is debated.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.